Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heterologous HER2 DNA vaccine
- Development stage
- Unknown
- Lead developer
- Helixmith
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The heterologous HER2 DNA vaccine is an investigational therapeutic cancer vaccine platform designed to overcome immune tolerance to self-antigens in HER2-expressing malignancies, such as breast cancer. This vaccination strategy typically utilizes DNA plasmids encoding xenogeneic (heterologous) HER2 sequences (such as human HER2, rat Neu, or hybrid human/rat HER2 constructs), often delivered via intramuscular injection combined with electroporation. By presenting a slightly foreign (heterologous) version of the HER2 antigen, the vaccine breaks immunological tolerance and stimulates robust, cross-reactive humoral and cellular (T-cell) immune responses against self-HER2 overexpressed on tumor cells. Some specific candidates within this class, such as VM206RY, employ a heterologous prime-boost regimen combining a DNA plasmid primer with a recombinant adenoviral vector boost to further enhance antigen-specific immunity.
- Other names
- heterologous HER2/neu DNA vaccineheterologous human/rat HER2 DNA vaccinexenogeneic HER2 DNA vaccine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on heterologous HER2 DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heterologous HER2 DNA vaccine.